Amgen Tops Analysts’ Profit Estimates, Raises 2015 Forecast

Updated on

Amgen Inc. posted second-quarter profit that topped analysts’ estimates, driven by higher sales of rheumatoid arthritis drug Enbrel and lower operating expenses. The biotech company also raised its revenue and earnings forecast for the year.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.